Mechanism of immunomodulatory drugs in multiple myeloma

SEDLAŘÍKOVÁ, Lenka, Lenka KUBICZKOVÁ, Sabina ŠEVČÍKOVÁ and Roman HÁJEK. Mechanism of immunomodulatory drugs in multiple myeloma. Leukemia Research. 2012, vol. 36, No 10, p. 1218–1224. ISSN 0145-2126. doi:10.1016/j.leukres.2012.05.010.

Basic information

• Original name: Mechanism of immunomodulatory drugs in multiple myeloma
• Authors: SEDLAŘÍKOVÁ, Lenka (203 Czech Republic, guarantor, belonging to the institution), Lenka KUBICZKOVÁ (203 Czech Republic, belonging to the institution), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution) and Roman HÁJEK (203 Czech Republic, belonging to the institution).
• Edition: Leukemia Research, 2012, 0145-2126.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: United Kingdom of Great Britain and Northern Ireland
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 2.764
• RIV identification code: RIV/00216224:14110/12:00057538
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.1016/j.leukres.2012.05.010
• UT WoS: 000308044100002
• Keywords in English: Multiple myeloma; Treatment; Immunomodulatory drugs; Thalidomide; Lenalidomide; Pomalidomide
• Tags: International impact

Abstract

Multiple myeloma is the second most common hematological cancer in the world. It is characterized by accumulation of malignant plasma cells in the bone marrow, osteolytic lesions and monoclonal immunoglobulins in blood/urine. With the introduction of immunomodulatory drugs into the treatment protocol, the outcome of multiple myeloma patients has dramatically improved with more than 30% of patients surviving for 10 years thus shifting multiple myeloma to a treatable condition.

Links

• GAP304/10/1395, research and development project: Name: Analýza klonálních progenitorů plazmatických buněk u monoklonálních gamapatií

Investor: Czech Science Foundation

• MSM0021622434, plan (intention): Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií

Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies

• NT11154, research and development project: Name: Úloha mitotické disrupce v B lymfocytech u mnohočetném myelomu

Investor: Ministry of Health of the CR